Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis

Comparative Medicine

Volumn 58, Issue 1, 2008, Pages 68-75

  Van Andel, Roger ^a,d   Sherwood, Robert ^a   Gennings, Chris ^c   Lyons, C Richard ^b   Hutt, Julie ^a   Gigliotti, Andrew ^a   Barr, Ed ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; CLINICAL FEATURE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FEVER; LD 50; MACACA; MALE; NONHUMAN; PLAGUE; YERSINIA PESTIS;

AEROSOLS; ANIMALS; ANTICONVULSANTS; APPETITE; BACTERIAL VACCINES; BODY TEMPERATURE; CERCOPITHECUS AETHIOPS; GABA MODULATORS; MACACA FASCICULARIS; MACACA MULATTA; MOTOR ACTIVITY; PLAGUE; PLAGUE VACCINE; SPECIES SPECIFICITY; TILETAMINE; YERSINIA PESTIS; ZOLAZEPAM;

EID: 40949102730     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adamovicz JJ, Worsham PL. 2006. Plague. In: Swearengen J, editor. Biodefense research metholodogy and animal models. Boca Raton: Taylor & Francis. p 107-135.
2. Bubeck SS, Cantwell AM, Dube PH. 2007. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 75:697-705.
3. Clark AR, Chambers CB, Muir D, Newhouse MT, Paboojian S, Schuler C. 2007. The effect of biphasic inhalation profiles on the deposition and clearance of coarse (6.5 μm) bolus aerosols. J Aerosol Med 20:75-82.
4. Davis KJ, Fritz DL, Pitt ML, Welkos SL, Worsham PL, Frielander AM. 1996. Pathology of experimental pneumonic plague produced by fraction-1-positive and fraction-1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med 120:156-162.
5. Dixon WJ. 1965. The up-down method for small samples. J Am Stat Assoc 60:967-978.
6. Finegold MJ. 1969. Pneumonic plague in monkeys. An electron microscopic study. Am J Pathol 54:167-185.
7. Finegold MJ, Petery JJ, Berendt RF, Adams HR. 1968. Studies on the pathogenesis of plague. Blood coagulation and tissue responses of Macaca mulatta following exposure to aerosols of Pasteurella pestis. Am J Pathol 53:99-114.
8. Food and Drug Administration, Department of Health and Human Services. 2002. New drug and biological products: evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Regist 67:37988-37998.
9. Food and Drug Administration, National Institute of Allergy and Infectious Disease, and Department of Health and Human Services. October 13-14, 2004. Proceedings of the Animal Models and Correlates of Protection for Plague Vaccines Workshop. Marriott Gaithersburg Washingtonian Center, Gaithersburg (MD): Department of Health and Human Services.
10. Gage KL, Dennis DT, Tsai TF. 1996. Prevention of plague: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 45(RR-14):1-15.
11. Girard JM, Wagner DM, Vogler AJ, Keys C, Allender CJ, Drickamer LC, Keim P. 2004. Differential plague-transmission dynamics determine Yersinia pestis population genetic structure on local, regional, and global scales. Proc Natl Acad Sci U S A 101:8408-8413.
12. Gonder JC. 2003. Demands for rhesus monkeys in biomedical research: a workshop report. ILAR J 44:222-235.
13. Guyton AC. 1947. Measurement of respiratory volumes of laboratory animals. Am J Physiol 150:70-77.
14. Hartings JM, Roy CJ. 2004. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J Pharmacol Toxicol Methods 49:39-55.
15. Honko AN, Sriranganathan N, Lees CJ, Mizel SB. 2006. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74:1113-1120.
16. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. 2000. Plague as a biological weapon, medical and public health management. JAMA 283:2281-2290.
17. Krebs KC, Jin ZY, Rudersdorf R, Hughes AL, O'Connor DH. 2005. Unusually high frequency MHC class I alleles in Mauritian-origin cynomolgus macaques. J Immunol 175:5230-5239.
18. Lawler SH, Sussman RW, Taylor LL. 1995. Mitochondrial DNA of Mauritian macaques (Macaca fascicularis): an example of the founder effect. Am J Phys Anthropol 96:133-141.
19. Leuchte N, Berry N, Kohler B, Almond N, LeGrand R, Thorstensson R, Titti F, Sauermann U. 2004. MhcDRB sequences from cynomolgus macaques (Macacca fascicularis) of different origin. Tissue Antigens 63:529-537.
20. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. 2005. Plague bacteria target immune cells during infection. Science 309:1739-1741.
21. Marshall JD Jr, Harrison DN, Rust JH Jr, Cavanaugh DC. 1971. Serological response of rhesus monkeys (Macaca mulatta) to immunization and infection with Pasteurella pestis. Proc Soc Exp Biol Med 138:738-741.
22. Mett V, Lyons J, Musiychuk K, Chichester JA, Brasil T, Couch R, Sherwood R, Palmer GA, Streatfield SJ, Yusibov V. 2007. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 25:3014-3017.
23. Meyer KF, Smith G, Foster L, Brookman M, Sung M. 1974. Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J Infect Dis 129 Suppl:S85-S112.
24. Meyer KF, Smith G, Foster LE, Marshall JD Jr, Cavanaugh DC. 1974. Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffkine and freeze-dried plague vaccine. J Infect Dis 129 Suppl:S30-S36.
25. Olfert E, Godson DL. 2000. Humane endpoints for infectious disease animal models in humane endpoints for animals used in biomedical research and testing. ILAR Journal 41:99-104.
26. Overheim KA, DePaolo W, DeBord KL, Morrin EM, Anderson DM, Green NM, Brubaker RR, Jabri B, Schneewind O. 2005. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 73:5152-5159.
27. Perry RD, Fetherston JD. 1997. Yersinia pestis - etiologic agent of plague. Clin Microbiol Rev 10:35-66.
28. Pitt L. 2006. Personal communication.
29. Roggenkamp A, Geiger AM, Leitritz L, Kessler A, Heesemann J. 1997. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphisms of V antigen. Infect Immun 65:446-451.
30. Roy CJ, Pitt LM. 2006. Infectious disease aerobiology: aerosol challenge methods. In: Swearengen J, editor. Biodefense research metholodogy and animal models. Boca Raton: Taylor & Francis. p 61-76.
31. Sibal LR, Samson KJ. 2001. Nonhuman primates: a critical role in current disease research. ILAR J 42:74-84.
32. Sikoski P, Banks ML, Gould R, Young RW, Wallace JM, Nader MA. 2007. Comparison of rectal and infrared thermometry for obtaining body temperature in cynomolgus macaques (Macaca fascicularis). J Med Primatol 36:381-384.
33. Starnbach MN, Bevan MJ. 1994. Cells infected with Yersinia present an epitope to class I MHC-restricted CTL. J Immunol 153:1603- 1612.